The biopharmaceutical company has seen shares rise 44.5% in less than two months.
News & Analysis: Neurocrine Biosciences
The company's Ingrezza continues to power its revenue and profitability growth.
NBIX earnings call for the period ending March 31, 2020.
The company's second commercial drug will launch later this year.
The biotech trounced Wall Street revenue and earnings estimates thanks to strong sales for its tardive dyskinesia drug.
NBIX earnings call for the period ending December 31, 2019.
Rapid sales growth for its tardive dyskinesia drug fueled investor optimism.
Which biotech was a 37-bagger?
NBIX earnings call for the period ending September 30, 2019.
With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.